Edwards Lifesciences Corporation Share Price
Stocks
EW
US28176E1082
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 94.37 USD | +2.59% |
|
+5.25% | +10.70% |
| 30/06 | BTIG Adjusts Price Target on Edwards Lifesciences to $110 From $100, Maintains Buy Rating | MT |
| 30/06 | Edwards Lifesciences Secures US FDA Approval for Ecliptis System | MT |
| Market Cap | 5.3TCr 4.63TCr 4.25TCr 3.96TCr 7.51TCr 5,04300Cr 7.64TCr 51TCr 20TCr 2,47300Cr 20TCr 19TCr 8,52200Cr | P/E 2026 * |
33.7x | P/E 2027 * | 28.8x |
|---|---|---|---|---|---|
| Enterprise Value | 4.95TCr 4.32TCr 3.97TCr 3.7TCr 7.02TCr 4,71100Cr 7.14TCr 48TCr 19TCr 2,31100Cr 19TCr 18TCr 7,96200Cr | EV / Sales 2026 * |
7.33x | EV / Sales 2027 * | 6.46x |
| Free-Float |
87.23% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Edwards Lifesciences Corporation
| 1 day | +2.59% | ||
| 1 week | +5.25% | ||
| Current month | +4.32% | ||
| 1 month | +7.04% | ||
| 3 months | +16.13% | ||
| 6 months | +10.70% | ||
| Current year | +10.70% |
| 1 week | 89.33 |  | 94.47 |
| 1 month | 83.17 | | 94.47 |
| Current year | 74.66 | | 94.47 |
| 1 year | 72.3 | | 94.47 |
| 3 years | 58.93 | | 96.12 |
| 5 years | 58.93 | | 131.73 |
| 10 years | 27.04 | | 131.73 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 58 | 11/05/2023 | |
Theodora Mistras
DFI | Director of Finance/CFO | 43 | 29/05/2026 |
| Chief Tech/Sci/R&D Officer | 51 | 01/09/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 69 | 07/05/2024 | |
Kieran Gallahue
BRD | Director/Board Member | 62 | 10/02/2015 |
| Director/Board Member | 58 | 11/05/2023 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 30/06 | Fiscal year | Executive/Senior Manager | 1,857 | 0.0003% | ||
| 17/06 | Sell | Chief Executive Officer | -523 | 0.0001% | ||
| 29/05 | Sell | Controller/Auditor | -568 | 0.0001% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.59% | +5.25% | +22.27% | +0.04% | 5.3TCr | |
| +1.97% | +6.35% | +24.19% | +0.32% | 19TCr | |
| +5.87% | +6.02% | -20.81% | +24.59% | 14TCr | |
| +2.17% | +4.80% | -1.58% | -17.53% | 14TCr | |
| +4.83% | +1.53% | -56.92% | -16.55% | 6.4TCr | |
| +1.39% | +2.13% | -25.49% | -32.59% | 4.38TCr | |
| -2.02% | -0.71% | +8.50% | +8.68% | 3.77TCr | |
| +0.31% | +2.74% | +6.23% | +42.30% | 3.71TCr | |
| +1.09% | +1.06% | -13.67% | -19.29% | 2.95TCr | |
| +4.24% | +6.68% | -18.20% | -4.06% | 2.9TCr | |
| Average | +2.18% | +2.36% | -7.55% | -1.41% | 7.65TCr | |
| Weighted average by Cap. | +2.48% | +3.34% | -3.31% | -0.15% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 674.8Cr 589.64Cr 541.45Cr 504.94Cr 957.25Cr 64TCr 973.4Cr 6.52TCr 2.53TCr 32TCr 2.53TCr 2.48TCr 1,08600Cr | 741.05Cr 647.53Cr 594.61Cr 554.51Cr 1.05TCr 71TCr 1.07TCr 7.16TCr 2.77TCr 35TCr 2.78TCr 2.72TCr 1,19200Cr |
| Net income | 162.43Cr 141.93Cr 130.33Cr 121.54Cr 230.42Cr 15TCr 234.3Cr 1.57TCr 608.15Cr 7.58TCr 609.89Cr 596.63Cr 26TCr | 189.11Cr 165.25Cr 151.74Cr 141.51Cr 268.27Cr 18TCr 272.8Cr 1.83TCr 708.06Cr 8.83TCr 710.08Cr 694.65Cr 30TCr |
| Net Debt | -348.23Cr -304.28Cr -279.42Cr -260.57Cr -493.99Cr -33TCr -502.32Cr -3.36TCr -1.3TCr -16TCr -1.31TCr -1.28TCr -56TCr | -507.26Cr -443.24Cr -407.02Cr -379.57Cr -719.58Cr -48TCr -731.72Cr -4.9TCr -1.9TCr -24TCr -1.9TCr -1.86TCr -82TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/26/03 | $94.37 | +2.59% | 31,74,029 |
| 01/26/01 | $91.99 | +1.69% | 42,84,007 |
| 30/26/30 | $90.46 | -0.79% | 36,27,318 |
| 29/26/29 | $91.18 | +0.44% | 36,06,384 |
| 26/26/26 | $90.78 | +1.18% | 1,44,20,825 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- EW Stock
Select your edition
All financial news and data tailored to specific country editions
